The Role of Pharmaceutical Biotechnology in the Fight against Viral Pandemics

Author(s): Nikolaos E. Labrou

Journal Name: Current Pharmaceutical Biotechnology

Volume 22 , Issue 1 , 2021


Become EABM
Become Reviewer
Call for Editor

-->

REFERENCES

[1]
Taubenberger JK, Morens DM. Influenza: The once and future pandemic. Public Health Rep 2010; 125(Suppl. 3): 16-26.
[2]
Sun H, Xiao Y, Liu J, et al. Prevalent Eurasian avian-like H1N1 swine influenza virus with 2009 pandemic viral genes facilitating human infection. Proc Natl Acad Sci USA 2020; 117(29): 17204-10.
[3]
Matveeva T, Khafizova G, Sokornova S. In search of herbal anti-SARS-Cov2 compounds. Front Plant Sci 2020; 11589998
[4]
Bolarin JA, Oluwatoyosi MA, Orege JI, Ayeni EA. Ibrahim, Y.A.; Adeyemi, S.B.; Tiamiyu, B.B.; Gbadegesin, L.A.; Akinyemi, T.O.; Odoh, C.K.; Umeobi, H.I.; Adeoye, A.B. Therapeutic drugs for SARS-CoV-2 treatment: Current state and perspective. Int Immunopharmacol 2020; 90107228
[5]
Mascola JR, Fauci AS. Novel vaccine technologies for the 21st century. Nat Rev Immunol 2020; 20(2): 87-8.
[6]
Luo H, Zhao M, Tan D, et al. Anti-COVID-19 drug screening: Frontier concepts and core technologies. Chin Med 2020; 15(1): 115.
[7]
Dunning J, Thwaites RS, Openshaw PJM. Seasonal and pandemic influenza: 100 years of progress, still much to learn. Mucosal Immunol 2020; 13: 566-73.
[8]
Mani JS, Johnson JB, Steel JC, et al. Natural product-derived phytochemicals as potential agents against coronaviruses: A review. Virus Res 2020; 284197989
[9]
Martinez MA. Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob Agents Chemother 2020; 64(5) pii:e00399-20.
[10]
Chung YH, Beiss V, Fiering SN, Steinmetz NF. COVID-19 vaccine frontrunners and their nanotechnology design. ACS Nano 2020; 14(10): 12522-37.
[11]
Kaur SP, Gupta V. COVID-19 vaccine: A comprehensive status report. Virus Res 2020; 288198114
[12]
Singh JA, Upshur REG. .E.G. The granting of emergency use designation to COVID-19 candidate vaccines: implications for COVID-19 vaccine trials.Lancet Infect. Dis., 2020; S1473-3099(20)30923..
[13]
Alpdagtas S, Ilhan E, Uysal E, Sengor M, Ustundag CB, Gunduz O. Evaluation of current diagnostic methods for COVID-19. APL Bioeng 2020; 4(4)041506
[14]
Capell T, Twyman RM, Armario-Najera V, Ma JK, Schillberg S, Christou P. Potential applications of plant biotechnology against SARS-CoV-2. Trends Plant Sci 2020; 25(7): 635-43.
[http://dx.doi.org/10.1016/j.tplants.2020.04.009]
[15]
Castillo-Henríquez L, Brenes-Acuña M, Castro-Rojas A, Cordero-Salmerón R, Lopretti-Correa M, Vega-Baudrit JR. Biosensors for the detection of bacterial and viral clinical pathogensSensors, (Basel). 2020; 20: p. (23)6926.
[16]
Pardi N, Weissman D. Development of vaccines and antivirals for combating viral pandemics. Nat Biomed Eng 2020; 4: 1128-33.
[17]
Kangabam R, Sahoo S, Ghosh A, et al. Next-generation computational tools and resources for coronavirus research: From detection to vaccine discovery. Comput Biol Med 2020; 128104158
[18]
Zhou X, Jiang X, Qu M, Aninwene GE. 2nd, Jucaud, V.; Moon, J.J.; Gu, Z.; Sun, W.; Khademhosseini, A. Engineering antiviral vaccines. ACS Nano 2020; 14(10): 12370-89.
[19]
Booz GW, Zouein FA. Science unites a troubled world: Lessons from the pandemic. Eur J Pharmacol 2020; 890173696
[20]
Wang F, Kream RM, Stefano GB. An Evidence based perspective on mRNA-SARS-CoV-2 vaccine development. Med Sci Monit 2020; 26e924700
[21]
Weng Y, Li C, Yang T, et al. The challenge and prospect of mRNA therapeutics landscape. Biotechnol Adv 2020; 40107534
[22]
Walsh EE, Frenck R, Falsey AR, et al. RNA-Based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study MedRxiv 2020. 2020.08.17.20176651.
[23]
Jackson LA, Anderson EJ, Rouphael NG, et al. 2nd, Padilla, M.; Mascola, J.R.; Neuzil, K.M.; Bennett, H.; Sun, W.; Peters, E.; Makowski, M.; Albert, J.; Cross, K.; Buchanan, W.; Pikaart-Tautges, R.; Ledgerwood, J.E.; Graham, B.S.; Beigel, J.H. mRNA-1273 study group. An mRNA Vaccine against SARS-CoV-2 - Preliminary report. N Engl J Med 2020; 383(20): 1920-31.
[24]
EU Clinical Trials Register. A Phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19. 21 April. 2020. EudraCT 2020-001228-32.
[25]
Bar-Zeev N, Inglesby T. COVID-19 vaccines: Early success and remaining challenges. Lancet 2020; 396(10255): 868-9.


free to download

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 22
ISSUE: 1
Year: 2021
Published on: 30 December, 2020
Page: [1 - 3]
Pages: 3
DOI: 10.2174/138920102201201231102955

Article Metrics

PDF: 31
HTML: 2